Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC.

Masahiro TsuboiRoy S HerbstThomas JohnTerufumi KatoMargarita MajemChristian GrohéJie WangJonathan Wade GoldmanShun LuWu-Chou SuFilippo de MarinisFrances A ShepherdKi Hyeong LeeNhieu Thi LeArunee DechaphunkulDariusz KowalskiLynne PooleAna BolanosYuri RukazenkovYi-Long Wunull null

Published in: The New England journal of medicine (2023)

-mutated, stage IB to IIIA NSCLC. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
epidermal growth factor receptor
brain metastases
wild type
lymph node
tyrosine kinase
free survival
prognostic factors